AstraZeneca Eyes $400B Merger with Bristol-Myers

British pharmaceutical company AstraZeneca is in talks with American firm Bristol Myers Squibb for a merger deal valued at up to $400 billion, aiming to create one of the largest pharmaceutical companies in the world. The likelihood of the deal being completed has increased in recent months. AstraZeneca's market capitalization is approximately £196 billion, while Bristol Myers Squibb’s is around $133 billion. If successful, the deal would strengthen the British company's focus on the U.S. market, especially following the elevated status of its listing on the New York Stock Exchange in June.

Size: 120%Text Size

Notice: This Is an AI-Generated Summary

Display The Full Article